W R Tracey

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo
    D R Knight
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Pfizer Inc, 3125 Eastern Point Road, Groton, CT 06340, USA
    J Pharmacol Exp Ther 297:254-9. 2001
  2. ncbi request reprint Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility
    A Guzman-Perez
    Pfizer Global Research and Development, Pfizer Inc, Groton CT 06340, USA
    Bioorg Med Chem Lett 11:803-7. 2001
  3. ncbi request reprint Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury
    W Ross Tracey
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, MS8220 3125, Eastern Point Rd, Groton, CT 06340, USA
    Am J Physiol Heart Circ Physiol 285:H2780-7. 2003
  4. ncbi request reprint Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1)
    W Ross Tracey
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Cardiovasc Drug Rev 21:17-32. 2003
  5. ncbi request reprint Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart
    W R Tracey
    Department of Cardiovascular and Metabolic Diseases, Pfizer Inc, Groton, CT 06340, USA
    Cardiovasc Res 33:410-5. 1997
  6. ncbi request reprint Selective activation of adenosine A3 receptors with N6-(3-chlorobenzyl)-5'-N-methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via KATP channel activation
    W R Tracey
    Department of Cardiovascular and Metabolic Diseases, Pfizer Inc, Groton, CT 06340, USA
    Cardiovasc Res 40:138-45. 1998
  7. ncbi request reprint Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury
    W R Tracey
    Department of Cardiovascular and Metabolic Diseases, Pfizer, Incorporated, Groton, Connecticut 06340, USA
    Am J Physiol Heart Circ Physiol 279:H1447-52. 2000
  8. ncbi request reprint Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor
    W Ross Tracey
    Pfizer Global Research and Development, MS8220 3125, Eastern Point Rd, Groton, CT 06340, USA
    Am J Physiol Heart Circ Physiol 286:H1177-84. 2004
  9. ncbi request reprint Cloning, expression and pharmacological characterization of rabbit adenosine A1 and A3 receptors
    R J Hill
    Department of Cardiovascular and Metabolic Diseases, Pfizer Inc, Groton, Connecticut, USA
    J Pharmacol Exp Ther 280:122-8. 1997
  10. ncbi request reprint The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor
    Michael P Deninno
    Pfizer Global Research and Development, Groton NewLondon Laboratories, Groton, CT 06340, USA
    Bioorg Med Chem Lett 16:2525-7. 2006

Collaborators

  • D Dalvie
  • S P Kennedy
  • Ravi B Marala
  • Anthony A Fossa
  • A Guzman Perez
  • Michael P Deninno
  • Li J Yu
  • H James Harwood
  • Garrett Gross
  • M Avkiran
  • John Auchampach
  • Anthony J Milici
  • D R Knight
  • William P Magee
  • Justin G Chapman
  • R J Hill
  • Tina C Wan
  • A Guzman-Perez
  • David M Flynn
  • R T Wester
  • Hugh Clements-Jewery
  • Yasushi Mio
  • Wai Meng Kwok
  • Zhi Dong Ge
  • Martin W Bienengraeber
  • Akihito Tampo
  • David R Plowchalk
  • Delvin R Knight
  • Walter C Soeller
  • Peter Wisniecki
  • Steve S Gernhardt
  • Judith L Treadway
  • Carolyn B Levy
  • Andrew H Smith
  • Wayne A Boettner
  • Mary C Allen
  • Fiona J Sutherland
  • Gayatri Deshmukh
  • Jill C Sutt
  • Hans A Stukenbrok
  • Gretchen E Beckius
  • J T MacAndrew
  • M C Allen
  • W W Day
  • W A Novomisle
  • J A Brown
  • A H Smith
  • E R Cook
  • W P Magee
  • D M Flynn
  • J X Kong
  • C J Mularski
  • A R Buchholz
  • S S Ellery
  • E S Hamanaka
  • R B Ruggeri
  • P J Kowalczyk
  • W Weng
  • C F Hoth
  • J J Oleynek
  • M A Kiron
  • R A Buchholz

Detail Information

Publications18

  1. ncbi request reprint A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injury in vitro and in vivo
    D R Knight
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Pfizer Inc, 3125 Eastern Point Road, Groton, CT 06340, USA
    J Pharmacol Exp Ther 297:254-9. 2001
    ..Zoniporide represents a novel class of potent NHE-1 inhibitors with potential utility for providing clinical cardioprotection...
  2. ncbi request reprint Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility
    A Guzman-Perez
    Pfizer Global Research and Development, Pfizer Inc, Groton CT 06340, USA
    Bioorg Med Chem Lett 11:803-7. 2001
    ..The potency and selectivity of zoniporide may be due to the conformation that the molecule adopts due to the presence of a cyclopropyl and a 5-quinolinyl substituent on the central pyrazole ring of the molecule...
  3. ncbi request reprint Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury
    W Ross Tracey
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, MS8220 3125, Eastern Point Rd, Groton, CT 06340, USA
    Am J Physiol Heart Circ Physiol 285:H2780-7. 2003
    ..CP-532,903 and CP-608,039 represent a novel class of human A3 receptor-selective agonists that may prove suitable for investigation of the clinical cardioprotective efficacy of A3 receptor activation...
  4. ncbi request reprint Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1)
    W Ross Tracey
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Cardiovasc Drug Rev 21:17-32. 2003
    ..Zoniporide represents a novel class of potent and selective human NHE-1 inhibitors with potential utility for providing cardioprotection in a clinical setting...
  5. ncbi request reprint Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart
    W R Tracey
    Department of Cardiovascular and Metabolic Diseases, Pfizer Inc, Groton, CT 06340, USA
    Cardiovasc Res 33:410-5. 1997
    ..The aim of this study was to determine whether selective activation of the adenosine A3 receptor reduces infarct size in a Langendorff model of myocardial ischemia-reperfusion injury...
  6. ncbi request reprint Selective activation of adenosine A3 receptors with N6-(3-chlorobenzyl)-5'-N-methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via KATP channel activation
    W R Tracey
    Department of Cardiovascular and Metabolic Diseases, Pfizer Inc, Groton, CT 06340, USA
    Cardiovasc Res 40:138-45. 1998
    ....
  7. ncbi request reprint Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury
    W R Tracey
    Department of Cardiovascular and Metabolic Diseases, Pfizer, Incorporated, Groton, Connecticut 06340, USA
    Am J Physiol Heart Circ Physiol 279:H1447-52. 2000
    ..Furthermore, combining zopolrestat with an A(3) agonist allows a reduction in the zopolrestat concentration while maintaining an equivalent degree of cardioprotection...
  8. ncbi request reprint Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor
    W Ross Tracey
    Pfizer Global Research and Development, MS8220 3125, Eastern Point Rd, Groton, CT 06340, USA
    Am J Physiol Heart Circ Physiol 286:H1177-84. 2004
    ....
  9. ncbi request reprint Cloning, expression and pharmacological characterization of rabbit adenosine A1 and A3 receptors
    R J Hill
    Department of Cardiovascular and Metabolic Diseases, Pfizer Inc, Groton, Connecticut, USA
    J Pharmacol Exp Ther 280:122-8. 1997
    ..The results will facilitate further in-depth studies of the roles of A1 and A3 receptors in adenosine-mediated cardioprotection in rabbits, which can now be based on the appropriate recombinant rabbit A1 and A3 receptor pharmacology...
  10. ncbi request reprint The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor
    Michael P Deninno
    Pfizer Global Research and Development, Groton NewLondon Laboratories, Groton, CT 06340, USA
    Bioorg Med Chem Lett 16:2525-7. 2006
    ..High aqueous solubility, required for the intended parenteral route of administration, was achieved by the presence of one or two basic amine functional groups...
  11. pmc Cardioprotective efficacy of zoniporide, a potent and selective inhibitor of Na+/H+ exchanger isoform 1, in an experimental model of cardiopulmonary bypass
    Hugh Clements-Jewery
    Centre for Cardiovascular Biology and Medicine, King s College London, The Rayne Institute, St Thomas Hospital, London
    Br J Pharmacol 142:57-66. 2004
    ....
  12. ncbi request reprint Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals
    H James Harwood
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Groton, Connecticut 06340, USA
    J Biol Chem 278:37099-111. 2003
    ..Taken together, These observations indicate that isozyme-nonselective ACC inhibition has the potential to favorably affect risk factors associated with the metabolic syndrome...
  13. ncbi request reprint 3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor
    Michael P Deninno
    PGRD Groton Laboratories, Pfizer Inc, Groton, Connecticut 06340, USA
    J Med Chem 46:353-5. 2003
    ..Herein, we report on the discovery and synthesis of compound 7. This amino nucleoside agonist possesses unprecedented levels of selectivity for the human adenosine A(3) receptor...
  14. ncbi request reprint A novel nonpeptidic caspase-3/7 inhibitor, (S)-(+)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin reduces myocardial ischemic injury
    Justin G Chapman
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Pfizer Inc, Groton, CT 06340, USA
    Eur J Pharmacol 456:59-68. 2002
    ..Furthermore, these data indicate that cardioprotection via caspase-3/7 inhibition is attainable via a small molecule (nonpeptidic) inhibitor, a necessary step in making this approach therapeutically viable...
  15. ncbi request reprint Differing cardioprotective efficacy of the Na+/Ca2+ exchanger inhibitors SEA0400 and KB-R7943
    William P Magee
    Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Pfizer Incorporated, Groton, Connecticut 06340, USA
    Am J Physiol Heart Circ Physiol 284:H903-10. 2003
    ..NCX inhibition represents an attractive approach for achieving clinical cardioprotection...
  16. ncbi request reprint Zoniporide: a potent and highly selective inhibitor of human Na(+)/H(+) exchanger-1
    Ravi B Marala
    Department of Cardiovascular and Metabolic Diseases, MS 8220 3118, Pfizer Global Research and Development, Pfizer Inc, Eastern Point Road, Groton, CT 06340, USA
    Eur J Pharmacol 451:37-41. 2002
    ..All three compounds inhibited human platelet swelling with IC(50) values in low nanomolar range. From these results, we conclude that zoniporide represents a novel, potent and highly selective NHE-1 inhibitor...
  17. pmc The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel
    Tina C Wan
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
    J Pharmacol Exp Ther 324:234-43. 2008
    ..We conclude that CP-532,903 is a highly selective agonist of the mouse A(3)AR that protects against ischemia/reperfusion injury by activating sarcolemmal K(ATP) channels...
  18. ncbi request reprint The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits
    David M Flynn
    Department of Cardiovascular, Metabolic and Endocrine Diseases, Pfizer Global Research and Development, Pfizer Inc, Groton, CT 06340, USA
    Cardiovasc Drugs Ther 19:337-46. 2005
    ..05 vs. VEH). Thus, at a clinically relevant plasma concentration, glipizide did not limit the cardioprotective effects of IPC, and is unlikely to increase the severity of cardiac ischemic injury...